Rezultati pretraživanja
  1. 10. ruj 2019.

    "Never forget the person in all the effort we make towards cures" - such an important reminder to us all!

  2. Since the OMP regulation was installed, nearly 2000 positive opinions for orphan designations have been adopted by COMP and the EC, resulting in 165 authorised OMPs across the EU (March 2019)

  3. 12. stu 2019.

    Delighted to be attending the World Orphan Drug Congress in Barcelona this week! Stop by and say 👋🏼 at stand 38!

  4. 13. stu 2019.

    Full house at hosting a roundtable at World Orphan Drug Congress. Dr. Yannick Loonus: "How could Artificial Intelligence improve uncovering unmet needs in rare diseases and enhance patient identification"

  5. What a great opportunity to be able to take the stage not once, but twice at the 10th and West Coast 2019. Honored to present with my good friend, Founder of Organization for Rare Diseases India, USA on "Buildi…

  6. 24. ruj 2019.

    interims - combination of Venn and has given us a strong platform to build full-service, high margin consultancy to offer services to fast-growing market

  7. On 3 June we will publish our briefings on the pharmaceutical incentive review . Do not miss it and sign up for our newsletter:

  8. 9. sij 2019.

    Looking for some good news on a Wednesday morning? For the first time EVER, comprised a majority of novel drugs approved by in 2018!! Now that’s what I call progress!

    Prikaži ovu nit
  9. 14. stu 2019.

    Day 2 at the World Orphan Drug Congress in Barcelona. Happy to help raise awareness of

  10. 8. tra 2019.

    Happy to announce that our President and CEO, Krishnan Nandabalan, will present at this year’s on April 10th, at 3:40 pm. Stop by if you’d like to see how ML and AI can accelerate and de-risk drug development for .

  11. are all set up at the World Orphan Drug Congress in Barcelona! 🇪🇸 ✨Interesting workshops this morning; including discussion on how to create sustainable access models for gene and other advanced therapies

  12. 13. velj 2019.

    Great kickoff of symposium by . 1- we are not faced w/ a tsunami of putting healthcare budgets @ risk 2-there are system failures & misconceptions hampering 3- a bold proposal on increased EU cooperation!

  13. 28. velj 2019.

    Excellent talk of Dr Verdes on , in A Corunna, Spain. antitrypsin augmentation therapy: How is it possible such a high cost for a drug that takes so long on the market? ⁦⁩ ⁦⁩ ⁦

  14. 17. lip 2019.

    Ready to discuss and today with at Square Brussels!

  15. 10. tra 2019.

    Kicking off with an intro by Dolon on the risky & costly business model of developing . How so? Check the graph assessing of the economic viability. Reds = costs; greens = potential revenues...that then need to adjust for risks.

  16. 28. sij

    issues formal compulsory acquisition notices to shareholders who have not yet accepted the Offer (2.47 Open Orphan shares for every one hVIVO share)

  17. 9. sij 2019.

    Currently discussing rare diseases with David Snow, CBO at at

  18. From in Philadelphia, Minoryx announces first patient dosed in Phase II clinical trial in Friedreich's

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.